Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | F2 | P00734 | 2/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanidine SCHEMBL2703343 | 0.77 | CA2 (0.48) | CA2CA1F2PRSS1PRSS2 | |
| SCHEMBL627731 | 0.77 | CA2 (0.48) | CA2CA1F2PRSS1PRSS2 | |
| SCHEMBL3928419 | 0.73 | CA2 (0.44) | CA2CA1F2PRSS1PRSS2 | |
| SCHEMBL1618240 | 0.72 | CA2 (0.48) | CA2CA1F2PRSS1PRSS2 | |
| SCHEMBL25708327 | 0.70 | CA2 (0.52) | CA2CA1CA7CA13 | |
| SCHEMBL10789031 | 0.70 | CA2 (0.52) | CA2CA1CA7CA13 | |
| SCHEMBL28817388 | 0.70 | — | — | |
| SCHEMBL23804913 | 0.70 | CA1 (0.41) | CA2CA1 | |
| SCHEMBL27547666 | 0.70 | CA2 (0.41) | CA2CA1F2PRSS1PRSS2 | |
| SCHEMBL193624 | 0.69 | KDM4E (0.35) | CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105408344-B | Peptide-resin conjugates and uses thereof | 佩特雷化学和生物制药学实验室有限公司 | 2020-08-11 | — | — | CN | claimed |
| EP-3010930-B1 | PEPTIDE-RESIN CONJUGATE AND USE THEREOF | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S A (GR) | 2019-09-18 | — | — | EP | claimed |
| WO-2004093821-A2 | TREATMENT OF ANTHRAX INFECTION USING INHIBITORS OF LETHAL FACTOR PROTEASE ACTIVITY | HAWAII BIOTECH, INC. (US) | 2004-11-04 | — | — | WO | claimed |
| EP-1324983-A1 | PROCESS FOR PREPARING DISTAMYCIN DERIVATIVES | Pharmacia Italia S.p.A. (IT) | 2003-07-09 | — | — | EP | claimed |
| WO-2002002523-A1 | PROCESS FOR PREPARING DISTAMYCIN DERIVATIVES | PHARMACIA ITALIA S.P.A. (IT) | 2002-01-10 | — | — | WO | claimed |
| EP-3649146-B1 | APELIN PEPTIDES AND USES THEREOF | UNIV ALBERTA (CA) | 2024-06-26 | — | — | EP | disclosed |
| EP-3853202-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ModernaTX, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-3830094-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | Mutabilis (FR) | 2021-06-09 | — | — | EP | disclosed |
| CN-105408344-B | Peptide-resin conjugates and uses thereof | 佩特雷化学和生物制药学实验室有限公司 | 2020-08-11 | — | — | CN | disclosed |
| US-20200239537-A1 | APELIN PEPTIDES AND USES THEREOF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2020-07-30 | — | — | US | disclosed |
| US-10723776-B1 | Apelin peptides and uses thereof | THE GOVERNERS OF THE UNIVERSITY OF ALBERTA (CA) | 2020-07-28 | — | — | US | disclosed |
| EP-3649146-A1 | APELIN PEPTIDES AND USES THEREOF | The Governors of the University of Alberta (CA) | 2020-05-13 | — | — | EP | disclosed |
| EP-1150979-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-11-07 | — | — | EP | disclosed |
| WO-2001040224-A1 | DIKETOPIPERAZINE DERIVATIVES TO INHIBIT THROMBIN | NOVOSCIENCE PHARMA INC. (CA) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001036003-A2 | SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES | DRUG INNOVATION & DESIGN, INC. (US) | 2001-05-25 | — | — | WO | disclosed |
| WO-2001014324-A1 | SELECTIVE INHIBITORS OF THE UROKINASE PLASMINOGENE ACTIVATORS | WILEX AG (DE) | 2001-03-01 | — | — | WO | disclosed |
| WO-2000047578-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | disclosed |
| US-6072075-A | Guanidinylation reagents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-06-06 | — | — | US | disclosed |
| EP-0983232-A2 | GUANIDINYLATION REAGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998052917-A2 | GUANIDINYLATION REAGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723776-B1 | Apelin peptides and uses thereof | APLNR, MME, ANPEP | CA2 2853/4885CA1 2841/4885F2 1247/4885 |
| US-20200239537-A1 | APELIN PEPTIDES AND USES THEREOF | APLNR, MME, ANPEP | CA2 2853/4885CA1 2841/4885F2 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.